亚日韩在线中文字幕亚洲,国产在线播放鲁啊鲁视频,张柏芝手扒性器全部图片,亚洲成无码电影在线观看

是否是腫瘤細胞：0
物種來源：褐鼠
運輸方式：凍存運輸
器官來源：大腦
細胞形態(tài)：其他
ATCC Number：CRL-2949?
相關(guān)疾?。浩渌膊?br /> 年限：fetus, 20 days gestation
數(shù)量：大量
生長狀態(tài)：貼壁生長
規(guī)格：48T Designations: F98_npEGFRvIII
Depositors: ?R.F. Barth
Biosafety Level:2
Shipped: frozen
Medium & Serum: See Propagation Growth Properties:adherent
Organism: Rattus norvegicus
Morphology:glial


Source: Organ: brain
Disease: undifferentiated malignant glioma
Breed: CD Fischer
Permits/Forms:In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Isolation: Isolation date: April 2001
Receptors:Epidermal Growth Factor Receptor vIII (EGFRvIII), expressed (verified at ATCC )
Tumorigenic:YES
Age: fetus, 20 days gestation
Comments:Epidermal Growth Factor Receptor (EGFR)-expressing F98 glioma cells (F98_EGFR ) were produced by transfecting F98 (ATCC CRL-2397 ) with an expression vector containing human EGFR_vIII cDNA. EGFR_vIII is a truncated extracellular mutant of the EGF receptor commonly found in glioblastomas that confers enhanced tumorigenic behavior. The receptors are very weakly phosphorylated. This cell line has been used for in vivo studies of molecular targeting of EGFR_vIII in syngeneic Fischer rats [PubMed: 15671565].
Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium:

0.2 mg/ml G -418

fetal bovine serum to a final concentration of 10%

Subculturing: Protocol: Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.

1. Remove and discard culture medium.
2. Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.05% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
3. Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
   Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37.0°C to facilitate dispersal.
4. Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
5. Add appropriate aliquots of the cell suspension to new culture vessels.

Subcultivation ratio: A subcultivation ratio of 1:6 to 1:10 is recommended.
Medium renewal: Every 2 to 3 days
Note: If cells are cultured continuously, add 0.6 mg/ml G-418 to the complete growth medium for a passage about once a month.

Preservation: Freeze medium: complete growth medium, 95%; DMSO, 5%
liquid nitrogen vapor phase
Doubling Time: about 17 hours
Related Products:Recommended medium (without the additional serum described under ATCC Medium): ATCC 30-2002
Recommended serum: ATCC 30-2020
Phosphate-buffered saline: ATCC 30-2200
Cell culture tested DMSO: ATCC 4-X
Parental Cell Line: F98 (CRL-2397)
Also derived from F98 (CRL-2397) : CRL-2949 (F98_EGFR
References: 16173105: Yang W, et al. Development of a Syngeneic Rat Brain Tumor Model Expressing EGFRvIII and Its Use for Molecular Taregeting Studies with Monoclonal Antibody L8A4. Clin. Cancer Res. 11(1): 341-350, 2005. PubMed: 15671565
16173106: Yang W, et al. Convection enhanced delivery of boronated epidermal growth factor for molecular targeting of EGFR positive gliomas. Cancer Res. 62: 6552-6558, 2002. PubMed: 12438250
16173107: Barth RF, et al. Molecular targeting of the epidermal growth factor receptor for neutron capture therapy of gliomas. Cancer Res. 62(11): 3159-3166, 2002. PubMed: 12036929
16173108: Wu G, et al. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. 5(1): 52-59, 2006. PubMed: 16432162.
16173109: Wu G, et al. Molecular targeting and treatment of an epidermal growth factor receptor-positive glioma using boronated cetuximab. Clin. Cancer Res. 13(4): 1260-1268, 2007. PubMed: 17317838
16173110: Yang W, et al. Molecular targeting and treatment of composite EGFR and EGFRvIII-positive gliomas using boronated monoclonal antibodies. Clin. Cancer Res. 14(3): 883-891, 2008. PubMed: 18245552